IGPH.SW
Price:
$0.0015
Market Cap:
$539.93K
IGEA Pharma N.V. commercializes health-tech and med-tech products and devices in in the United States and the Netherlands. It offers Alz1, an at-home lab test kit to measure non-bound copper in the blood; dietary supplement products to reduce blood heavy metals content under the Alz1 Tab brand; and COVID19 rapid test for the detection of IgM and IgG SARS-CoV-2 related antibodies. The company also provides dry aerosol generators for air and inanimate environmental surfaces sanitization, as well as air sterilization and purification devices. In addition, it engages in laboratory analysis. The company was incorporated in 2015 and is headquartered in Hoofddorp, the Netherlands.
Industry
Medical - Diagnostics & Research
IPO Date
2018-12-20
Stock Exchange
SIX
Ticker
IGPH.SW
According to IGEA Pharma N.V.’s latest financial reports and current stock price. The company's current PE Ratio is -0.05. This represents a change of -98.05% compared to the average of -2.57 of the last 4 quarters.
The mean historical PE Ratio of IGEA Pharma N.V. over the last ten years is -67.89. The current -0.05 PE Ratio has changed -92.64% with respect to the historical average. Over the past ten years (40 quarters), IGPH.SW's PE Ratio was at its highest in in the December 2022 quarter at -0.44. The PE Ratio was at its lowest in in the March 2018 quarter at -83.61.
Average
-67.89
Median
-38.29
Minimum
-165.48
Maximum
-0.93
Discovering the peaks and valleys of IGEA Pharma N.V. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.43%
Maximum Annual PE Ratio = -0.93
Minimum Annual Increase = -97.88%
Minimum Annual PE Ratio = -165.48
| Year | PE Ratio | Change |
|---|---|---|
| 2022 | -0.93 | -97.88% |
| 2021 | -43.86 | -73.50% |
| 2020 | -165.48 | 1.43% |
| 2019 | -10.79 | -67.03% |
| 2018 | -32.73 | -78.69% |
The current PE Ratio of IGEA Pharma N.V. (IGPH.SW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-70.09
5-year avg
-50.76
10-year avg
-67.89
IGEA Pharma N.V.’s PE Ratio is greater than EvoNext Holdings S.A. (-6.64), less than Newron Pharmaceuticals S.p.A. (15.39), greater than Santhera Pharmaceuticals Holding AG (-2.38), greater than ObsEva S.A. (-0.31), greater than WISeKey International Holding AG (-8.10),
| Company | PE Ratio | Market cap |
|---|---|---|
| -6.64 | $5.64M | |
| 15.39 | $364.88M | |
| -2.38 | $157.84M | |
| -0.31 | $140.61K | |
| -8.10 | $115.87M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like IGEA Pharma N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like IGEA Pharma N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is IGEA Pharma N.V.'s PE Ratio?
How is the PE Ratio calculated for IGEA Pharma N.V. (IGPH.SW)?
What is the highest PE Ratio for IGEA Pharma N.V. (IGPH.SW)?
What is the 3-year average PE Ratio for IGEA Pharma N.V. (IGPH.SW)?
What is the 5-year average PE Ratio for IGEA Pharma N.V. (IGPH.SW)?
How does the current PE Ratio for IGEA Pharma N.V. (IGPH.SW) compare to its historical average?